FDA gives guidance on brand, generic names in ads

Share this article:
The FDA issued guidance clarifying narrow questions of scientific or generic name placement in ads and labeling in different media, including electronic media.

The agency, said the guidance, “frequently receives inquiries about the placement, size, prominence and frequency of the proprietary (or brand) name and the established (scientific, generic) name in promotional materials.” Most of these inquiries are concerned with either the juxtaposition of brand and generic names or with “problems stemming from obscuring the presentation of, or minimizing disclosure of, the established name.”

The guidance distinguishes between name placement in “running text (i.e., body copy), and in headlines, taglines, logos, footnotes, graphs or pictures, along with stipulating different requirements for drugs with a single active ingredient and for combo drugs. For “electronic and computer-based promotional labeling and advertisements” on single-ingredient drugs, the agency noted that online labeling and advertising typically feature running text equivalent to many pages of traditional printed text. Where the brand name does not appear in running text, the scientific name must accompany the brand name in each instance. In the body copy, the scientific name may appear once per screen.

“It is narrow, but there is new information,” said Wendy Blackburn, EVP at Overland Park, KS-based agency Intouch Solutions. “For example, it addresses the rules for brand and generic mentions on website ‘screens,' but doesn't articulate how a screen is defined. Do they mean a full page from top to bottom of the scroll, or the portion I see on my monitor? At what screen resolution? And what if I'm looking at the screen in a partially-sized browser window, or on my iPad or smartphone or other device?”

Moreover, Blackburn suggested, the rules for videos, DTC TV ads and websites could require that companies perform a complete internal review of all promotional materials across channels, including brand logos, at great expense.  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...